Since 1991, Roche Diagnostics has been serving in the leading Medical Faculties, Ministry of Health Research and Training Hospitals, private hospitals and laboratories of Turkey. Starting out with the aim of becoming one of Turkey's leading healthcare company in light of Roche's global expertise and experience, Roche Diagnostics Turkey improves patients' lives within Centralized and Point of Care Solutions, Molecular Diagnostics and Diabetes Care areas with its innovative and high-tech devices for professional and personal use and its biochemistry, hormone, genetics, molecular and cancer test portfolio. Having approximately 270 employees today, Roche Diagnostics Turkey also attaches great importance to the professional services it offers, aiming to increase the quality of people's lives and the quality of service of healthcare organizations and taking into account its position in emergency services.
Roche Group was founded in 1896 to find better ways to prevent, diagnose, and treat diseases and make a sustainable contribution to society. Being the largest biotechnology company in the world, Roche has dedicated itself to improving healthcare standards as well as developing groundbreaking medicines in the fields of oncology, hematology, immunology, infectious diseases, ophthalmology, and neuroscience. As a world leader in the In Vitro Diagnostics market, it establishes long-term partnerships with universities and healthcare institutions worldwide.
With innovation in its DNA, Roche focuses on pushing the boundaries of the future in its area of activity in order to guide scientific discoveries and improve patients' lives. For more than 120 years, it continues to apply new technologies in the field of personalized healthcare to meet the needs of people from today and to pioneer the emerging digitalization trends.
As of 2018, Roche Group, with its headquarters in Basel, Switzerland, operates in more than 100 countries with approximately 94 thousand employees. Investing 11 billion Swiss Francs in R&D in 2018, Roche achieved a turnover of 56.8 billion Swiss Francs. Roche Group is the owner of Genentech located in the USA and the majority shareholder of Chugai Pharmaceutical located in Japan.
Initiating its first operations in Turkey in a building in Esentepe with its staff of eight people, Roche Pharmaceuticals has been carrying out its works from the head office in Maslak-Uniq, Istanbul since 2015. Celebrating its 60th year of operation in 2018, Roche Pharmaceuticals offers innovative solutions to patients, their relatives and healthcare professionals in Turkey, simultaneously with the rest of the world, with its products for the treatment of diseases in oncology, hematology, rheumatology, transplantation, and respiratory areas.
Roche Pharmaceuticals believes in the need to immediately offer medical solutions to people with its future-oriented innovative approach. In order to define a vision in line with this purpose, it has created a road map with all of its employees to improve patients' lives, aligning with both the global and Turkey strategies. In line with its goals, which have emerged on the road to Vision 2022, it continues to work today to meet the needs of tomorrow and support the continuity of sustainable development.
Roche Diagnostics also offers three different levels of consulting solutions to healthcare organizations in order to invest in the right technology, improve efficiency and quality, facilitate adaptation to change, and make savings:
- Technical Consulting: At the planning stage before the process begins.
- Process Consulting: In the elimination of downtime in the course of the process.
- Strategic Consulting: In adding or developing new processes.
The working area of our consultancy services is not limited to the blood bank, molecular laboratory, pathology laboratory and central laboratories, but also includes areas operating outside the laboratory such as sampling, logistics, point-of-care services, and sample acceptance.